[A clinical study of acute lymphoblastic leukemia in adolescents: a single center experience]

To explore the clinical and laboratory characteristics, treatment, prognostic factors of acute lymphoblastic leukemia (ALL) in adolescents.

Adolescents de novo ALL patients in Blood Disease Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences from September 1999 to September 2013 were enrolled in this study. Clinical data, therapeutic effect and prognostic factors were retrospectively analyzed.

Of all 94 patients, 91 patients were treated in our center. The overall complete remission (CR) rate was 96.7% (88/91), CR rate after one cycle was 91.2%(83/91). The median follow-up time was 18 months. In all patients, the 6-year anticipated overall survival (OS) rate and disease free survival (DFS) rate were (47.6 ± 6.7)% and (45.4 ± 6.0)% respectively. In standard risk ALL patients , 6-year anticipated OS rate and DFS rate were (65.7 ± 8.1)% and (65.3 ± 7.4)%. Hyperleukocytosis (white blood cell count ≥30 × 10(9)/L in B-ALL; ≥100 × 10(9)/L in T-ALL), Ph(+) , MLL(+) , hypodiploid were risk factors associated with poor clinical outcome.

The therapeutic effect and clinical outcome in adolescents with ALL are relatively favorable, especially in standard risk group. In high risk ALL patients, allogeneic hematopoietic stem cell transplantation may improve therapeutic efficacy.